INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

ME Staff 8-k
-
0

INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On November15, 2017, the Board of Directors (the “Board”) of Incyte Corporation (the “Company”) amended the Company’s bylaws (as so amended, the “Bylaws”). The amendments (a)provide for a majority vote standard for the election of directors in uncontested director elections whereby director nominees must receive a majority of the votes cast in order to be elected to the Board (previously, the Company’s Corporate Governance Guidelines (the “Guidelines”) contained a similar standard, and the portion of the standard in those Guidelines relating to resignations of nominees who do not receive such a majority vote remains in effect); and (b)effect certain minor corrections.

The foregoing description of the Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Bylaws, a copy of which is filed as Exhibit3.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


INCYTE CORP Exhibit
EX-3.1 2 a17-27253_1ex3d1.htm EX-3.1 Exhibit 3.1   BYLAWS OF INCYTE CORPORATION   (amended as of November 15,…
To view the full exhibit click here

About INCYTE CORPORATION (NASDAQ:INCY)

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company’s second oral JAK1 and JAK2 inhibitor is baricitinib.